BioSpace News Archive

Innovation Pharmaceuticals announced that the Company has acquired a minority stake in Israel-based Squalus Medical, the inventor and developer of the StingRay Laser System, a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.

The global pressure relief devices market size is expected to reach USD 6.16 Billion in 2030 and register a revenue CAGR of 6.83% during the forecast period, according to the latest report by Reports and Data.

The global magnetic resonance imaging market is forecast to reach USD 10.33 Billion by 2030, according to a new report by Reports and Data.

VisAR, an augmented reality surgical navigation system from healthcare technology leader Novarad™, receives FDA 510(k) approval for precision guided intraoperative spine surgery.

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced plans to appear on the Benzinga All Access show on Friday, June 17, 2022.

Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market LLC on Thursday, June 16, under the new ticker symbols “ALVO” and “ALVOW”, respectively.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), today announced positive topline results from the first three arms of Part 3 of the EPIPHAST study for its AQST-109 epinephrine oral film.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2022 before the market open on Tuesday, July 12, 2022.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the appointment of Faye Feller, M.D., to Executive Vice President and Chief Medical Officer, effective July 9, 2022.